MABC969
Anti-PD-L2 Antibody, clone 24F.10C12
clone 24F.10C12, from mouse
別名:
Programmed cell death 1 ligand 2, B7-DC, B7 dendritic cell molecule, B7-H2, Butyrophilin B7-DC, CD273, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2
ログイン組織・契約価格を表示する
すべての画像(2)
About This Item
UNSPSCコード:
12352203
eCl@ss:
32160702
NACRES:
NA.41
おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified immunoglobulin
抗体製品タイプ
primary antibodies
クローン
24F.10C12, monoclonal
化学種の反応性
human
テクニック
flow cytometry: suitable
immunohistochemistry: suitable
neutralization: suitable
western blot: suitable
アイソタイプ
IgG2aκ
NCBIアクセッション番号
UniProtアクセッション番号
輸送温度
dry ice
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... PDCD1LG2(80380)
詳細
Programmed cell death 1 ligand 2 (UniProt Q9BQ51; also known as B7-DC, B7 dendritic cell molecule, B7-H2, Butyrophilin B7-DC, CD273, PD-1 ligand 2, PD-L2, PDCD1 ligand 2, Programmed death ligand 2) is encoded by the PDCD1LG2 (also known as B7DC, CD273, PDCD1L2, PDL2) gene (Gene ID 80380) in human. PD-1 and PD-1 ligands 1&2 (PD-L1 and PD-L2) are B7:CD28 family members that regulate T cell activation and peripheral tolerance. When engaged together with the TCR, the interaction of PD-1 with its ligands delivers an inhibitory signal to T cell proliferation and cytokine production. While PD-L1 is broadly expressed in hematopoietic and nonhematopoietic cells, PD-L2 expression is highly restricted to antigen presenting cells (APCs), including dendritic cells (DCs) and macrophages. The PD-1 pathway plays a key role in the progressive loss of effector T cell responses during chronic HIV infection. Under some conditions, blockade of this pathway is able to restore many T cell functions. PD-L2 is initially produced with signal peptide (a.a. 1-19) sequence, the removal of which yields the mature protein with a large extracellular (a.a. 20-220) region that contains an Ig-like V-type domain (a.a. 21-118) and an Ig-like C2-type domain (a.a. 122-203), followed by a transmembrane domain (a.a. 221-241) and a cytoplasmic tail (a.a. 242-273).
特異性
Clone 24F.10C12 immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L2, but not the untransfected cells or cells transfected with human PD-L1 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266). Reactivity toward spliced isoform 2 (PD-L2II) and isoform 3 (PD-L2III) has not been determined.
免疫原
Epitope: Extracellular domain.
Recombinant human PD-L2.
アプリケーション
Research Category
アポトーシス及び癌
アポトーシス及び癌
Research Sub Category
アポトーシス-追加
アポトーシス-追加
Flow Cytometry Analysis: 0.1 µg from a representative lot detected PD-L2-positive human PBMCs.
Flow Cytometry Analysis: A representative lot immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L2, but not the untransfected cells or cells transfected with human PD-L1 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected a small induction of surface PD-L2 expression on human PBMCs in culture upon IFN-gamma stimulation (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and employed to detect surface PD-L2 expression on PBMC-derived dendric cells (DCs). An upregulated PD-L2 expression was seen among mature DCs (mDC) than immature DCs (iDC), the levels of PD-L2 were reduced upon pretreatment of mDC with IL-10 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected surface PD-L2 expression on tonsil-derived human follicular DCs (FDCs) (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: A representative lot competed against human PD-1 extracellular domain Ig fusion for the binding of exogenously expressed human PD-L2 on the surface of 300.19 murine pre-B lymphoma cells (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: DP-L2 blocking on the surface of PBMC-derived dendritic cells (DCs) by clone 24F.10C12 Fab fragment increased CD4+ T cell proliferation and cytokine production in allogenic cultures with immature DCs (iDC), mature DCs (mDC), and IL-10-treated mDCs. Dual blockage of both DP-L1 (by clone 29E.2A3 Fab fragment) and DP-L2 synergized the enhancing effect (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunohistsochemistry Analysis: A representative lot detected PD-L2 expression pattern in frozen human tonsil, placenta, fetal thymus and cardiac tissue sections (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunocytsochemistry Analysis: A representative lot detected an upregulated PD-L2 immunoreactivity in human CD14+ monocyte-derived macrophages (MDMs) following HIV-BaL infection, but not LPS stimulation by fluorescent immunocytochemistry using paraformaldehyde-fixed MDMs (Rodríguez-García, M., et al. (2011). J. Leukoc. Biol. 89(4) 507–515).
Flow Cytometry Analysis: A representative lot immunostained the surface of 300.19 murine pre-B lymphoma cells transfected with human PD-L2, but not the untransfected cells or cells transfected with human PD-L1 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected a small induction of surface PD-L2 expression on human PBMCs in culture upon IFN-gamma stimulation (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and employed to detect surface PD-L2 expression on PBMC-derived dendric cells (DCs). An upregulated PD-L2 expression was seen among mature DCs (mDC) than immature DCs (iDC), the levels of PD-L2 were reduced upon pretreatment of mDC with IL-10 (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Flow Cytometry Analysis: A representative lot was conjugated with FITC and detected surface PD-L2 expression on tonsil-derived human follicular DCs (FDCs) (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: A representative lot competed against human PD-1 extracellular domain Ig fusion for the binding of exogenously expressed human PD-L2 on the surface of 300.19 murine pre-B lymphoma cells (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Neutralizing Analysis: DP-L2 blocking on the surface of PBMC-derived dendritic cells (DCs) by clone 24F.10C12 Fab fragment increased CD4+ T cell proliferation and cytokine production in allogenic cultures with immature DCs (iDC), mature DCs (mDC), and IL-10-treated mDCs. Dual blockage of both DP-L1 (by clone 29E.2A3 Fab fragment) and DP-L2 synergized the enhancing effect (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunohistsochemistry Analysis: A representative lot detected PD-L2 expression pattern in frozen human tonsil, placenta, fetal thymus and cardiac tissue sections (Brown, J.A., et al. (2003). J. Immunol. 170(3):1257-1266).
Immunocytsochemistry Analysis: A representative lot detected an upregulated PD-L2 immunoreactivity in human CD14+ monocyte-derived macrophages (MDMs) following HIV-BaL infection, but not LPS stimulation by fluorescent immunocytochemistry using paraformaldehyde-fixed MDMs (Rodríguez-García, M., et al. (2011). J. Leukoc. Biol. 89(4) 507–515).
This Anti-PD-L2 Antibody, clone 24F.10C12 is validated for use in Western Blotting, Flow Cytometry, Neutralizing, Immunohistochemistry for the detection of PD-L2.
品質
Evaluated by Western Blotting in human thymus tissue lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected PD-L2 in 10 µg of human thymus tissue lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected PD-L2 in 10 µg of human thymus tissue lysate.
ターゲットの説明
~30 kDa observed. 28.85 kDa (isoform 1; PD-L2I), 18.76 kDa (isoform 2; PD-L2II), 18.64 kDa (isoform 3; PD-L2III) calculated.
物理的形状
Protein G Purified
Format: Purified
Purified mouse monoclonal IgG2aκ antibody in buffer containing PBS without preservatives.
保管および安定性
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
その他情報
Concentration: Please refer to lot specific datasheet.
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
MABC969:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Christophe Glorieux et al.
Redox biology, 38, 101780-101780 (2020-11-11)
K-ras mutations are major genetic events that drive cancer development associated with aggressive malignant phenotypes, while expression of the immune checkpoint molecule PD-L1 plays a key role in cancer evasion of the immune surveillance that also profoundly affects the patient
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）